DFTX · Definium Therapeutics, Inc. · Webcasts, Transcripts & Audio
$29.12
-0.26 (-0.88%)
At close · Nov 18
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$3.99B
Shares
136.90M
Volume · Nov 18
1.92M
Avg daily vol (3M)
1.96M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Definium Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Definium Therapeutics, Inc. (DFTX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-12-02
Definium Therapeutics, Inc. (DFTX) December 2, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-12-01
Definium Therapeutics, Inc. (DFTX) December 1, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-17
Definium Therapeutics, Inc. (DFTX) November 17, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-10
Definium Therapeutics, Inc. (DFTX) November 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-09
Definium Therapeutics, Inc. (DFTX) Q3 2026 Earnings Call Transcript
Confident tone
PTSD expansion
Regulatory progress and NDA filing
DT402 autism pipeline
Diluted EPS
$-0.46
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-08-06
Definium Therapeutics, Inc. (DFTX) Q2 2026 Earnings Call Transcript
Confident tone
DT120 ODT clinical efficacy in MDD (eMERGE)
Commercial launch preparation for DT120
DT120 regulatory path and FDA alignment
Diluted EPS
$-1.44
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-06-22
Definium Therapeutics, Inc. (DFTX) Q1 2026 Earnings Call Transcript
Confident tone
DT120 Phase III Program (MDD/GAD)
Pipeline Expansion (PTSD, ASD/DT402)
Regulatory Progress & DEA Scheduling
Diluted EPS
$-0.71
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Definium Therapeutics, Inc. (DFTX) Q4 2025 Earnings Call Transcript
Confident tone
Generalized Anxiety Disorder Program
DT120 ODT Pipeline Progress
Major Depressive Disorder Program
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Definium Therapeutics, Inc. (DFTX) Q3 2025 Earnings Call Transcript
Confident tone
Phase III MM120 readouts in GAD and MDD
ASCEND second Phase III in MDD
MM402 / R-enantiomer of MDMA in autism
Diluted EPS
$-0.78
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Definium Therapeutics, Inc. (DFTX) Q2 2025 Earnings Call Transcript
Confident tone
MM120 ODT Phase III trials
Clinical readout timeline
Phase IIb efficacy data
Diluted EPS
$-0.50
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Definium Therapeutics, Inc. (DFTX) Q1 2025 Earnings Call Transcript
Confident tone
Disease Burden and Market Opportunity
MM120 Phase 3 Program Execution
New Chief Commercial Officer Onboarding
Diluted EPS
$-0.35
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-06
Definium Therapeutics, Inc. (DFTX) Q4 2024 Earnings Call Transcript
Confident tone
MM120 Phase 3 GAD Program (Voyage and Panorama)
MDD Program (Emerge)
Regulatory Designations and IP
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Definium Therapeutics, Inc. (DFTX) Q3 2024 Earnings Call Transcript
Confident tone
MM120 ODT in GAD (Voyage and Panorama Phase 3 studies)
MM120 ODT in MDD (Emerge Phase 3 study)
Clinical execution and enrollment efficiency
Diluted EPS
$-0.27
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-12
Definium Therapeutics, Inc. (DFTX) Q2 2024 Earnings Call Transcript
Confident tone
MM120 Phase 3 in GAD
Expansion into MDD
FDA regulatory engagement
Diluted EPS
$-0.26
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Definium Therapeutics, Inc. (DFTX) Q1 2024 Earnings Call Transcript
Confident tone
MM120 Phase IIb results in GAD
Pipeline expansion and additional indications
ODT formulation and IP
Diluted EPS
$-1.14
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Definium Therapeutics, Inc. (DFTX) Q4 2023 Earnings Call Transcript
Confident tone
MM120 Phase 2b results in GAD
Phase 3 development and End-of-Phase 2 meeting
MM402 and R(-)-MDMA program in ASD
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Definium Therapeutics, Inc. (DFTX) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.45
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Definium Therapeutics, Inc. (DFTX) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.76
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Definium Therapeutics, Inc. (DFTX) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.65
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-09
Definium Therapeutics, Inc. (DFTX) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Definium Therapeutics, Inc. (DFTX) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.56
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Definium Therapeutics, Inc. (DFTX) Q2 2022 Earnings Call
Diluted EPS
$-0.60
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Definium Therapeutics, Inc. (DFTX) Q1 2022 Earnings Call
Diluted EPS
$-0.66
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-28
Definium Therapeutics, Inc. (DFTX) Q4 2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–24 of 24 webcasts
Key facts
CIK
1813814
CUSIP
24477V105
13F (30d)
343 filings
335 filers
Visit website
Investor relations